ロード中...
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure
BACKGROUND: Outcomes data among patients with heart failure (HF) with reduced ejection fraction treated with sacubitril/valsartan (SAC/VAL) are largely limited to clinical trial results. We compared hospitalization and healthcare costs among real‐world patients with HF with reduced ejection fraction...
保存先:
| 出版年: | J Am Heart Assoc |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6512093/ https://ncbi.nlm.nih.gov/pubmed/31023122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.011089 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|